1398 related articles for article (PubMed ID: 25046994)
1. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Kazim SF; Blanchard J; Dai CL; Tung YC; LaFerla FM; Iqbal IG; Iqbal K
Neurobiol Dis; 2014 Nov; 71():110-30. PubMed ID: 25046994
[TBL] [Abstract][Full Text] [Related]
2. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound.
Baazaoui N; Iqbal K
Alzheimers Res Ther; 2017 Jun; 9(1):45. PubMed ID: 28655344
[TBL] [Abstract][Full Text] [Related]
3. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice.
Wei W; Wang Y; Liu Y; Dai CL; Tung YC; Liu F; Iqbal K
Alzheimers Res Ther; 2020 Aug; 12(1):102. PubMed ID: 32854771
[TBL] [Abstract][Full Text] [Related]
4. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound.
Baazaoui N; Iqbal K
J Alzheimers Dis; 2017; 58(1):215-230. PubMed ID: 28387677
[TBL] [Abstract][Full Text] [Related]
6. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
Kazim SF; Iqbal K
Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice.
Blanchard J; Wanka L; Tung YC; Cárdenas-Aguayo Mdel C; LaFerla FM; Iqbal K; Grundke-Iqbal I
Acta Neuropathol; 2010 Nov; 120(5):605-21. PubMed ID: 20697724
[TBL] [Abstract][Full Text] [Related]
8. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
9. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
[TBL] [Abstract][Full Text] [Related]
10. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.
Dobarro M; Gerenu G; Ramírez MJ
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2245-57. PubMed ID: 23768694
[TBL] [Abstract][Full Text] [Related]
11. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease.
Garcia P; Youssef I; Utvik JK; Florent-Béchard S; Barthélémy V; Malaplate-Armand C; Kriem B; Stenger C; Koziel V; Olivier JL; Escanye MC; Hanse M; Allouche A; Desbène C; Yen FT; Bjerkvig R; Oster T; Niclou SP; Pillot T
J Neurosci; 2010 Jun; 30(22):7516-27. PubMed ID: 20519526
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
Wu X; Kosaraju J; Zhou W; Tam KY
ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
[TBL] [Abstract][Full Text] [Related]
13. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound.
Bolognin S; Buffelli M; Puoliväli J; Iqbal K
Neurobiol Aging; 2014 Sep; 35(9):2134-46. PubMed ID: 24702821
[TBL] [Abstract][Full Text] [Related]
14. Sex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice.
Kapadia M; Mian MF; Michalski B; Azam AB; Ma D; Salwierz P; Christopher A; Rosa E; Zovkic IB; Forsythe P; Fahnestock M; Sakic B
J Alzheimers Dis; 2018; 63(3):1191-1205. PubMed ID: 29710702
[TBL] [Abstract][Full Text] [Related]
15. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
16. Impaired Src signaling and post-synaptic actin polymerization in Alzheimer's disease mice hippocampus--linking NMDA receptors and the reelin pathway.
Mota SI; Ferreira IL; Valero J; Ferreiro E; Carvalho AL; Oliveira CR; Rego AC
Exp Neurol; 2014 Nov; 261():698-709. PubMed ID: 25128699
[TBL] [Abstract][Full Text] [Related]
17. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice.
Chen Y; Zhao Y; Dai CL; Liang Z; Run X; Iqbal K; Liu F; Gong CX
Exp Neurol; 2014 Nov; 261():610-9. PubMed ID: 24918340
[TBL] [Abstract][Full Text] [Related]
18. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
19. Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.
Hedberg MM; Clos MV; Ratia M; Gonzalez D; Lithner CU; Camps P; Muñoz-Torrero D; Badia A; Giménez-Llort L; Nordberg A
Neurodegener Dis; 2010; 7(6):379-88. PubMed ID: 20689242
[TBL] [Abstract][Full Text] [Related]
20. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
